Shares of Hologic, Inc. (NASDAQ:HOLX – Get Rating) have earned an average recommendation of “Buy” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $81.00.
A number of research analysts have issued reports on HOLX shares. Wells Fargo & Company downgraded Hologic from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $90.00 to $75.00 in a research note on Monday, April 25th. StockNews.com started coverage on Hologic in a research note on Thursday, March 31st. They issued a “buy” rating for the company. SVB Leerink upped their price objective on Hologic to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, May 17th. Finally, Citigroup reduced their price objective on Hologic from $78.00 to $75.00 in a research note on Thursday, April 28th.
In other news, insider Jan Verstreken sold 6,500 shares of the stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $78.80, for a total transaction of $512,200.00. Following the completion of the transaction, the insider now owns 64,191 shares in the company, valued at approximately $5,058,250.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.54% of the stock is currently owned by corporate insiders.
NASDAQ HOLX opened at $71.73 on Friday. The firm has a market capitalization of $17.89 billion, a P/E ratio of 11.82, a PEG ratio of 0.92 and a beta of 1.09. The business has a fifty day simple moving average of $75.62 and a 200 day simple moving average of $73.97. Hologic has a 12 month low of $61.52 and a 12 month high of $81.04. The company has a current ratio of 2.97, a quick ratio of 2.57 and a debt-to-equity ratio of 0.59.
Hologic (NASDAQ:HOLX – Get Rating) last released its quarterly earnings results on Wednesday, April 27th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.52. The business had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.28 billion. Hologic had a return on equity of 42.26% and a net margin of 28.79%. During the same period in the prior year, the firm posted $2.59 EPS. As a group, sell-side analysts predict that Hologic will post 5.54 EPS for the current fiscal year.
Hologic Company Profile (Get Rating)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- Get a free copy of the StockNews.com research report on Hologic (HOLX)
- Three Upgrades You Need To Pay Attention Too
- Consider These Dividend-Paying Stocks During Inflationary Times
- MarketBeat: Week in Review 6/6 – 6/10
- NIO (NYSE: NIO) Justifies Recent Rally
- HubSpot: A More Competitive Valuation
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.